for chronic asthma, 396–397

for COPD, 420t, 422

for rhinitis, 442

Fluticasone furoate (Flonase Sensimist), 441t

for allergic rhinitis, 442

for chronic asthma, 396

Fluticasone propionate (Dymista), 441t

for allergic rhinitis, 442

Fluvastatin, 46t, 55, 110t, 116, 117t, 120t

Fluvoxamine (Luvox), 1027t, 1738t, 1748

for depression, 2245

for depressive disorders, 1820t

for diabetes, 2226t

dosage, 1758

drug interaction with smoking, 1906t

for OCD, 1760

for PTSD, 1754

Fluvoxamine CR, for SAD, 1752

Fluzone High-Dose, 1361

Folate

alcohol withdrawal, 1896

for anemia, 1936

Folic acid, 958, 961

and pregnancy, 968, 969, 979

recommended daily allowance (RDA), 969

and women, 969

Fomepizole, 562

Fondaparinux, 189, 252

for ACS, 241t

for DVT, 187

in patients with HIT, 657

UFH and LMWH and, 177–178, 177t

Formaldehyde, 822t

Formoterol

for COPD, 421, 421t, 422

for EIA, 400

Fortaz (see Ceftazidime)

Fosamprenavir (FPV), 128, 914t

for HIV, 1579t

Fosaprepitant (Emend), 472t

Foscarnet (Foscavir), 742, 1613, 1649t, 1651

adjunctive therapy, 1608t

adjusted dosage, 1610t

advantages, 1608t

adverse effects of, 1334t, 1608t, 1612, 1647t

CrCl, 1610t

disadvantages, 1608t

dosing regimens, 1608t, 1612

for herpes labialis, 1651

important drug interactions, 1608t

intravitreal administration, 1613

monitoring requirement, 1609t

normal dosage, 1610t

precautions and contraindications, 1609t

to prevent nephrotoxicity, 1612

Foscavir (see Foscarnet), 1649t

Fosfomycin, for UTI, 1489, 1489t, 1491

Fosinopril, 281, 281t, 2223

in hypertension, 153t

Fosphenytoin, 55, 942t, 1288

in SE, 1299

for seizures, 1284t

FPV (see Fosamprenavir (FPV))

FreAmine HBC, 794t

FreAmine III, 794t

Frovatriptan, 1237, 1238t, 1239

FTC (see Emtricitabine (FTC))

Furazolidone, for giardiasis, 1707

Furosemide, 543–544, 546, 580, 589–590, 1991–1993, 2223

doses of, 277

for HF, 276–277

for hypercalcemia, 589t

for hypertension, 148

for nephrotic edema, 574

for PDA, 2179, 2180

urine osmolality and, 579

Fusidic acid, 914t

G

Gabapentin (Neurontin), 1180, 1181t, 1187t, 1189, 1194t, 1195, 1224, 1242, 1271t, 1272, 1279t, 1281,

1845

androgen deprivation therapy, 2097

for diabetes, 1145

for PHN, 1654

for seizures, 1284t

for vasomotor symptoms, 1036t

Gabapentinoids, 1193

Gabitril (see Tiagabine)

Gadolinium-based contrast (GBC) agents, 643

Galantamine

for Alzheimer’s disease, 2239

for vascular dementia, 2242

Gallium nitrate, for hypercalcemia, 589t, 590

Gamma-glutamyl transferase (GGT), 1894

γ-Hydroxybutyric acid (GHB), 1882

Ganciclovir (Cytovene), 742, 743, 744, 1613, 1649t

adjunctive therapy, 1608t

adjusted dosage, 1610t

advantages, 1608t

adverse effects of, 1334t, 1608t, 1647t

for CMV disease, 1607

CrCl, 1610t

disadvantages, 1608t

dose-limiting toxicity, 1607

dosing of, 1337t

dosing regimens, 1608t

ganciclovir-induced bone marrow suppression, 1607

for herpes simplex keratitis, 1168

important drug interactions, 1608t

induction dose of, 1607

intraocular implants, 1608–1609, 1613

intravitreal administration, 1613

mode of administration, 1607

monitoring requirement, 1609t

normal dosage, 1610t

precautions and contraindications, 1609t

Ganciclovir-foscarnet combination, for CMV retinitis, 1612

Garamycin (see Gentamicin)

Gardasil, 1359

GBC agents (see Gadolinium-based contrast (GBC) agents)

Gefitinib, 470t

Gelclair, 1975

Gemcitabine (Gemzar), 469t, 1978t, 1994t

for NSCLC, 2062t, 2064t

Gemfibrozil, 120t, 123, 124, 124t, 125, 606

Gemifloxacin (Factive), 1326t

Gemzar (see Gemcitabine)

Genistein, 1030

Gentamicin (Garamycin), 658, 659, 665, 669, 670–671, 822, 1165, 1325t, 1724

adverse effects of, 1332t

for bacterial endocarditis, 644, 645

for CAPD-associated peritonitis, 1476t

for chorioamnionitis, 996

for CNS infections, 1373t

p. 2302

p. 2303

for cystic fibrosis, 461t

dosing of, 1337t

for enterococcal endocarditis, 1397t, 1398

for gram-negative aerobes, 1327t

for NEC, 2183

nephrotoxic antibiotic, 644

for UTI, 1497t

vancomycin and, 1398

Gentian violet, 1626

Geodon (see Ziprasidone)

GGT (see Gamma-glutamyl transferase (GGT))

GHB (see γ-Hydroxybutyric acid (GHB))

Ginger, for NVP, 976t

Ginseng, 942t

Glargine, 980

Glatiramer acetate, 1222

adverse effects of, 1225

patient characteristics and other factors associated with reduced adherence to, 1226t

patient counseling points for, 1226t

Gleevec (see Imatinib)

Glimepiride, 127, 1122, 1140

for type 2 diabetes, 1122, 1136, 1137

Glipizide, 127

for type 2 diabetes, 1122

GLP (see Glucagon-like peptide-1 agonists (GLP))

Glucagon, 689t, 1140

for hypoglycemia, 1107

Glucagon-like peptide-1 agonists (GLP)

adverse effects of, 1126–1127

contraindications and precautions of, 1127

dosage and clinical use, 1127

drug interactions, 1127

efficacy of, 1127

mechanism of action, 1126

pharmacokinetics of, 1126

Glucarpidase, 1992

Glucocorticoids

antenatal administration, 994

for fetal lung maturation, 986

for NVP, 976t

for prostate cancer, 2094

Glucomannan, 765t

Glucosamine, 867

Glucose, 585–586

administration, 611

for hyperkalemia, 587t

hypokalemia and, 583t

tablets for hypoglycemia, 1107

Glucosidase inhibitors

adverse effects of, 1125

contraindications and precautions of, 1125

dosage and clinical use, 1126

drug interactions, 1125

efficacy of, 1126

mechanism of action, 1125

pharmacokinetics of, 1125

Glutamatem, 1224

Glutamine, 1986

Glutathione, 1986

Glyburide, 127, 678, 981, 1001

for type 2 diabetes, 1122

Glycerol, 792

Glycoprotein IIb/IIIa inhibitors, 1312

, for ACS, 241t, 256t

Glycopyrrolate

for COPD, 420t

for end-of-life care, 89

Glycyrrhetinic acid, 1975

Gold, 881, 883

Golimumab, 881, 882, 895, 896t

for PsA, 842–843

Gonadotropin-releasing hormone (GnRH) agonists, 1019–1020, 1020t

adverse effects, 1022

for depressive disorders, 1815t

for endometriosis, 1021–1022

Gonadotropin-releasing hormone (GnRH) analogs, for IVF, 962–964

Gonadotropin-releasing hormone (GnRH) therapy, for prostate cancer, 2084, 2090

Goserelin (Zoladex), 1020t, 1021

Granisetron (Kytril), 472t

for PONV, 478t

Grastek, for allergic rhinitis, 435t

Grazoprevir, for HAV, 1688, 1689

Green tea, 765t

Griseofulvin, 942, 942t, 1624, 1624t, 1627

risk factor C, 1637

Guanabenz, 159, 2261t

Guanfacine, 159, 2261t

for ADHD, 1868t, 1870

Guarana, 765t

H

H2RAs (see Histamine-2 receptor antagonists (H2RAs))

HAART (see Highly active antiretroviral therapy (HAART))

Haemophilus influenzae type b (Hib), 1355, 1357–1358

Halcion (see Triazolam)

Haldol (see Haloperidol)

Halfan (see Halofantrine)

Halofantrine (Halfan), 1695

Haloperidol (Haldol), 472t, 1215, 1267, 1789t, 1797t, 1799t

drug interaction with smoking, 1906t

for end-of-life care, 89

for hyperprolactinemia, 1803

for OCD, 1760

for schizophrenia, 1793, 1793t

Haloperidol decanoate, 1795t

HAT (see Heparin-associated thrombocytopenia (HAT))

Havrix, 1357

Hawthorn, 304

HCTZ (see Hydrochlorothiazide (HCTZ))

Heat therapy, 1627

Helioplex, 852

Hemoglobin F, for vaso-occlusive complications, 1940

Heparin, 177t, 662, 1311–1312

for ACS, 241t

adverse effects of, 185–186

and breast milk, 1001

doses of, 183–184

dosing nomogram, 184, 185t

drug interaction with smoking, 1906t

duration of therapy, 184–185

hemorrhage from, 186

hypersensitivity reactions of, 186–187

induced thrombocytopenia, 186t

osteoporosis from, 186

protamine and, 187

reversal of effect, 187

therapeutic monitoring, 184

thrombocytopenia from, 185–186

for thrombosis, 176–177

Heparin-associated thrombocytopenia (HAT), 185

Heparinoids, 1311–1312

HepatAmine, 794t

HepAtasol, 794t

Hepatitis A (Hep A) vaccines, 1357 (see also Vaccination)

Hepatitis B immunoglobulin (HBIG), 1355

Hepatitis B (HepB) vaccine, 1355–1356 (see also Vaccination)

Hepatotoxicity

from isoniazid, 1435–1436

isoniazid–rifampin and, 1437

rifampin and, 1437

Herceptin (see Trastuzumab)

Heroin

and lactation, 1003t

for opioid withdrawalsyndrome, 1878

Hib polysaccharide conjugate vaccines (HbCV), 1358

HiDAC (see High-dose cytarabine (HiDAC))

High-dose cytarabine (HiDAC), 2025, 2028

Highly active antiretroviral therapy (HAART), 1596, 1597

and cryptococcosis, 1614

discontinuation of, 1598–1599

impact on CD4+lymphocytes, 1598

impact on opportunistic infections (OIs), 1598

and prevalence of CMV, 1607

Histamine-2 receptor antagonists (H2RAs), 484, 493t, 1215, 1216t

concomitant administration of, 484

for GER, 2162–2163, 2163t

for GERD, 508

and PPI, in combination, 508

in preventing SRMB, 514

for upper GI bleeding, 512–513

HIV protease inhibitors, 120t

H

M

GC

o

A

r

e

d

u

c

t

a

s

e

i

n

h

i

b

i

t

o

r

s

,

9

1

4

t

H

o

m

o

s

a

l

a

t

e

,

8

4

9

t

,

8

5

2

H

o

m

o

v

a

n

i

l

l

i

c

a

c

i

d

(

H

VA

)

,

2

0

0

3

H

o

o

d

i

a

,

7

6

5

t

H

S

(

s

e

e

H

yp

e

rt

o

n

i

c

S

a

l

i

n

e

(

H

S

)

)

H

u

m

a

l

o

g

(

s

e

e

I

n

s

u

l

i

n

l

i

s

p

r

o

)

H

u

m

a

n

e

ryt

h

r

o

p

o

i

e

t

i

n

-

e

p

o

e

t

i

n

a

l

fa

,

6

1

4

–

6

1

5

H

u

m

u

l

i

n

N

,

1

0

8

7

p. 2

3

0

3

p. 2

3

0

4

H

VA

(

s

e

e

H

o

m

o

v

a

n

i

l

l

i

c

a

c

i

d

(

H

VA

)

)

H

y

a

l

u

r

o

n

i

c

a

c

i

d

,

1

9

7

5

H

y

a

l

u

r

o

n

i

d

a

s

e

,

1

9

8

1

t

H

y

c

a

m

t

i

n

(

s

e

e

T

o

p

o

t

e

c

a

n

)

H

y

d

r

a

l

azi

n

e

,

1

5

7

t

,

2

9

4

,

3

3

5

t

,

3

4

4

,

9

8

6

,

9

8

7

,

2

2

6

1

t

c

o

ntr

a

in

dic

a

t

io

n

s

o

f,

3

4

4

do

s

e

s

o

f,

3

4

4

fo

r

H

F

,

2

7

1

fo

r

hyp

e

r

t

e

n

s

io

n

,

1

6

0

in

p

a

t

ie

nt

s

w

ith

C

K

D

,

6

1

7

H

y

d

r

o

c

h

l

o

ri

c

a

c

i

d

(

H

C

l

)

,

5

6

4

H

y

d

r

o

c

h

l

o

r

o

t

h

i

azi

d

e

(

H

C

T

Z)

,

2

2

2

3

fo

r

a

g

it

a

t

e

d

b

e

h

a

v

io

r

s

,

2

2

4

3

a

n

d

b

r

e

a

s

t

milk

,

1

0

0

2

fo

r

hyp

e

r

t

e

n

s

io

n

,

1

4

8

,

2

2

4–

2

2

5

H

y

d

r

o

c

o

d

o

n

e

,

1

1

8

7

t

H

y

d

r

o

c

o

rt

i

s

o

n

e

fo

r

B

P

D

,

2

1

7

5

fo

r

p

r

o

s

t

a

t

e

c

a

n

c

e

r

,

2

0

9

4

v

a

le

r

a

t

e

,

8

1

6

H

y

d

r

o

c

o

rt

i

s

o

n

e

c

r

e

a

m

(

Xe

r

e

s

e

)

,

1

6

5

0

H

y

d

r

o

m

o

rp

h

o

n

e

,

1

1

7

8

,

1

1

7

9

,

1

1

8

7

t

,

1

1

9

9

do

s

a

g

e

o

f,

1

1

9

9

t

H

y

d

r

o

m

o

rp

h

o

n

e

(

D

i

l

a

u

d

i

d

)

,

6

7

7

H

y

d

r

o

x

o

c

o

b

a

l

a

m

i

n

,

3

4

2

H

y

d

r

o

x

y

c

h

l

o

r

o

q

u

i

n

e

,

7

0

7

–

7

0

8

,

7

1

2

t

,

7

1

3

t

,

8

8

1

,

8

8

4

,

8

9

1

–

8

9

2

,

8

9

4

p

s

o

r

ia

s

is

a

n

d

,

8

3

4

H

y

d

r

o

x

y

c

i

t

ri

c

a

c

i

d

,

7

6

5

t

H

y

d

r

o

x

yp

y

ri

d

o

n

e

,

1

6

2

6

H

y

d

r

o

x

y

u

r

e

a

,

4

7

0

t

,

1

9

7

8

,

1

9

7

8

t

,

2

0

2

7

fo

r

v

a

s

o

-

o

c

c

lu

s

iv

e

c

o

mp

lic

a

t

io

n

s

,

1

9

4

0

H

y

d

r

o

x

yzi

n

e

(

Vi

s

t

a

ri

l

)

fo

r

N

V

P

,

9

7

5

,

9

7

6

t

fo

r

p

rur

itu

s

,

8

1

9

H

y

o

s

c

y

a

m

i

n

e

(

s

e

e

a

l

s

o

A

n

t

i

s

p

a

s

m

o

d

i

c

s

)

fo

r

e

n

d

-

o

flife

c

a

r

e

,

8

9

H

yp

e

rt

o

n

i

c

S

a

l

i

n

e

(

H

S

)

,

3

5

5

,

4

5

9

fo

r

a

ir

w

a

y

c

le

a

r

a

n

c

e

tr

e

a

tme

nt

,

4

5

9

H

yp

n

o

t

i

c

s

,

1

7

6

4

,

1

7

6

8

a

n

d

s

le

e

p

,

1

7

7

4

H

yp

o

g

l

y

c

e

m

i

c

s

,

9

8

0

–

9

8

1

I

Ibandronate, 2277, 2277t, 2278

Ibrutinib, 470t

Ibuprofen, 460, 870, 870t, 887, 888t, 1187t

for dysmenorrhea, 1015

for HF, 275

and hyperkalemia, 585

for PDA, 2179

Ibutilide, for AF, 315

ICE, for aggressive lymphomas, 2041–2042

Ice therapy, 915

Icodextrin, 661

Idamycin (see Idarubicin)

Idarubicin (Idamycin), 469t, 1979t, 1988

for AML, 2025

Idarucizumab, 1316

Idelalisib, 470t, 914t

IDV (see Indinavir (IDV))

Ifex (see Ifosfamide)

IFNs (see Interferons (IFNs))

Ifosfamide, 469t, 1991, 1991t

and cranial neuropathies, 1987

encephalopathic toxicity of, 1985

and encephalopathy, 1986

neurotoxicity of, 1985t

for osteosarcoma, 2008

for rhabdomyosarcoma, 2010, 2011

Iloperidone (Fanapt), 1797t, 1799t

for hyperprolactinemia, 1803

for schizophrenia, 1790, 1791t

Iloprost, 924

Imatinib (Gleevec), 128, 470t, 1977, 1990, 1996, 1996t, 2031

drug interactions with, 48–49

131

I-MIBG, 2006

Imidazoles, 1625

Imipenem-cilastatin (Primaxin), 1326t

for aerobic gram-positive cocci, 1326t

for anaerobes, 1328t

for CAPD-associated peritonitis, 1476t

for cystic fibrosis, 461t

dosing of, 1337t

for febrile neutropenia, 1561

for skin and soft tissue infections, 1550

for UTI, 1497t

Imipenem/meropenem/doripenem, for gram-negative aerobes, 1327t

Imipramine

for depressive disorders, 1819t, 1821t

hydrochloride, 2252

for panic disorder, 1748

Imiquimod, 1651

for genital warts, 1532

Immunoglobulin, 742

G antibodies, 455–456

for HAV, 1666

for HBV, 1675, 1680–1681

for Rh-associated HDN, 998–999

Immunoglobulin G (IVIG), for skin and soft tissue infections, 1551

Immunomodulators

for PsA, 842

for psoriasis, 836t

Immunosuppressants and lactation, 1003t

Immunotherapy

for allergic rhinitis, 434–435

for rhinitis, 444–445

Inactivated polio vaccine (IPV), 1355, 1358

Inapsine (see Droperidol)

Incretin, for type 2 diabetes, 1126

Indacaterol, for COPD, 420t, 421, 422

Indinavir (IDV), 128, 942t, 1579t

Indomethacin, 870t, 887, 888t, 993, 1187t

for hypercalcemia, 589t, 591

for PDA, 2179, 2180

Induction therapy, for AML, 2026–2028

Infanrix, 1357

Infliximab, 881, 882, 895, 896t

for IBD patients, 524

for inflammatory bowel disease, 522t

for PsA, 842–843

for treatment of CD, 531

for UC, 527–528

Influenza vaccine, 1360–1361

Inhaled β2

-agonists, 459

Inositol, 1849

Insulin

administration of, 611

adverse effects of, 1105–1108

clinical use of, 1091–1101

delivery of, 1091, 1093–1094

for diabetes, 167

for DKA management, 1111

endogenous, 1084

evaluation of, 1097–1098

for hyperkalemia, 587t

intensive vs. conventional glycemic control with, 1104t

measuring and injecting, 1094–1095, 1094f

mixing, 1099

monotherapy with type 2 diabetes, 1138–1139

pharmacodynamics of, 1084–1087, 1085t

pharmacokinetics of, 1084

premixed, 1139

stability, 1099

therapy, 980

therapy, basal, 1139

Insulin aspart (NovoLog), 1086

Insulin degludec (Tresiba), 1087

Insulin detemir (Levemir), 980, 1087

Insulin glargine (Lantus), 1087

Insulin glulisine (Apidra), 980, 1086

Insulin lispro (Humalog), 1085–1086

Interferon alpha, 469t

I

n

t

e

r

fe

r

o

n

s

(

I

F

N

s

)

fo

r

d

e

p

r

e

s

s

iv

e

dis

o

r

d

e

r

s

,

1

8

1

5

t

fo

r

H

B

V

,

1

6

7

7

fo

r

S

A

R

S

,

1

6

6

0

I

n

t

e

rl

e

u

k

i

n

-

2

,

fo

r

d

e

p

r

e

s

s

i

v

e

d

i

s

o

r

d

e

r

s

,

1

8

1

5

t

I

n

t

e

r

m

e

zz

o

,

fo

r

t

r

e

a

t

m

e

n

t

o

f

i

n

s

o

m

n

i

a

,

1

7

6

7

t

I

n

t

r

a

m

u

s

c

u

l

a

r

m

e

t

h

yl

p

r

e

d

n

i

s

o

l

o

n

e

,

9

2

5

I

n

t

r

a

n

a

s

a

l

c

o

rt

i

c

o

s

t

e

r

o

i

d

s

fo

r

a

lle

r

g

ic

r

h

init

is

,

4

3

3

fo

r

r

h

init

is

,

4

3

9

–

4

4

2

,

4

4

1

t

I

n

t

r

a

o

c

u

l

a

r

g

a

n

c

i

c

l

o

v

i

r

i

m

p

l

a

n

t

s

,

1

6

0

8

–

1

6

0

9

,

1

6

1

3

I

n

t

r

av

e

n

o

u

s

(

I

V)

a

l

b

u

m

i

n

i

n

fu

s

i

o

n

s

,

5

4

5

I

n

t

r

av

e

n

o

u

s

k

e

t

o

r

o

l

a

c

,

1

1

8

0

I

n

t

r

av

e

n

o

u

s

l

i

d

o

c

a

i

n

e

,

1

1

8

2

I

n

t

r

av

e

n

o

u

s

n

i

t

r

o

g

l

y

c

e

ri

n

,

2

9

7

I

n

v

a

n

z

(

s

e

e

E

rt

a

p

e

n

e

m

)

I

n

v

e

g

a

(

s

e

e

P

a

l

i

p

e

ri

d

o

n

e

)

I

o

d

i

n

e

s

,

1

6

2

6

a

n

d

p

r

e

gn

a

n

c

y

,

9

6

8

I

o

d

o

q

u

i

n

o

l

,

1

7

0

6

fo

r

a

me

b

ic

id

e

s

,

1

7

0

3

t

fo

r

a

me

b

ic

liv

e

r

a

b

s

c

e

s

s

,

1

7

0

3

t

fo

r

g

a

s

tr

o

int

e

s

t

in

a

l

dis

e

a

s

e

,

1

7

0

3

t

I

o

p

i

d

i

n

e

(

s

e

e

A

p

r

a

c

l

o

n

i

d

i

n

e

)

I

p

i

l

i

m

u

m

a

b

,

4

6

9

t

,

1

9

7

6

I

P

L

E

D

GE

p

r

o

g

r

a

m

,

8

3

0

I

p

r

a

t

r

o

p

i

u

m

b

r

o

m

i

d

e

(

A

t

r

o

v

e

n

t

)

,

4

4

0

t

fo

r

a

lle

r

g

ic

r

h

init

is

,

4

3

4

fo

r

B

P

D

,

2

1

7

5

fo

r

C

O

P

D

,

4

2

0

t

,

4

2

1

I

P

V

(

s

e

e

I

n

a

c

t

i

v

a

t

e

d

p

o

l

i

o

v

a

c

c

i

n

e

(

I

P

V)

)

I

rb

e

s

a

rt

a

n

,

fo

r

h

yp

e

rt

e

n

s

i

o

n

,

1

5

4

t

p. 2

3

0

4

p. 2

3

0

5

I

ri

n

o

t

e

c

a

n

,

4

6

9

t

,

1

9

7

6

,

1

9

9

6

fo

r

a

dv

e

r

s

e

e

ffe

c

t

s

,

2

0

8

0

fo

r

c

o

lo

n

c

a

n

c

e

r

,

2

0

7

3

drug

int

e

r

a

c

t

io

n

w

ith

s

mo

kin

g

,

1

9

0

6

t

fo

r

r

h

a

b

do

my

o

s

a

r

c

o

ma

,

2

0

1

0

,

2

0

1

1

fo

r

S

C

L

C

,

2

0

6

8

t

I

r

o

nfor

a

n

e

mia

,

1

9

3

0

a

n

d

dy

s

p

e

p

s

ia

,

4

8

7

GE

R

D

a

n

d

,

5

0

3

t

in

g

e

s

t

io

n

o

f,

a

s

s

e

s

s

me

nt

o

f,

7

0–

7

4

a

n

d

p

r

e

gn

a

n

c

y

,

9

6

8

–

9

6

9

I

r

o

n

d

e

x

t

r

a

n

,

6

1

4

fo

r

a

n

e

mia

,

1

9

3

1

,

1

9

3

2

,

1

9

3

3

inj

e

c

t

io

n

,

6

9

6

I

r

o

n

s

u

c

r

o

s

e

,

6

1

4

fo

r

a

n

e

mia

,

1

9

3

1

,

1

9

3

2

,

1

9

3

3

I

s

av

u

c

o

n

az

o

l

e

,

1

6

2

4

t

adverse effects of, 1334t

Isoflavone, 1030

Isoniazid, 484, 942

and allergic reactions, 1436

dosing of, 1337t

drug interactions with, 1436

hepatotoxicity from, 1435–1436

for HIV-infected and TB, 1616

and peripheral neuropathy, 1436

for tuberculosis, 53, 54t, 1429t, 1433

Isoproterenol, 363t

GERD and, 503t

for postoperative cardiac failure, 363t

Isopto Carpine (see Pilocarpine)

Isosorbide, 1158

Isosorbide-5-mononitrate, 550

Isosorbide dinitrate (BiDil), 221, 294, 295

Isotretinoin, 942t

for acne, 830–831

teratogenic effects, 973t

Isradipine, for chronic stable angina pectoris, 214

Itraconazole, 120t, 128, 484, 942t, 1615, 1624t, 1625, 1626t, 1627–1628

antifungal agents, 41

adverse effects of, 1334t

for chronic pulmonary blastomycosis, 1637

CNS penetration of, 1640

dosing, 1628

for S. schenckii, 1627

Ivabradine (Corlanor), 272

Ivacaftor (Kalydeco), 60

CFTR potentiator, 451–452

IV antipseudomonal antibiotics, 463

IV colistin, 460

IV diltiazem, for AF, 345

Ivermectin, 1711

for lice, 1704t